OX401 – Onxeo

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

PARP & DDR Inhibitors Summit 2020 The DNA Damage Response Therapeutics Summit brings together the leading pharma and biotech companies […]

Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation […]